Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:38:29.948Z.
Calculation as of: 2026-10-06T20:38:29.948Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ddbbc57cb4d55ad36c9ea810397d6785d98e1ed361c578be0001995c9b2602d4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$7.87M
EV/Sales Ratio
N/A
TTM Avg
4.01x
3Y Avg
4.01x
5Y Avg
4.01x
Market Cap
$8.04M
EV/Sales Ratio
N/A
TTM Avg
2618.99x
3Y Avg
2618.99x
5Y Avg
2618.99x
Market Cap
$8.14M
EV/Sales Ratio
N/A
TTM Avg
802.02x
3Y Avg
903.36x
5Y Avg
873.57x
Market Cap
$7.67M
EV/Sales Ratio
N/A
TTM Avg
1162726.42x
3Y Avg
640219.29x
5Y Avg
640219.29x
Market Cap
$7.64M
EV/Sales Ratio
24.52x
TTM Avg
19.77x
3Y Avg
15.30x
5Y Avg
133.58x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | $7.92M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | N/A | 4.01x | 4.01x | 4.01x |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | N/A | 2618.99x | 2618.99x | 2618.99x |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | 4.76x | 2.16x | 2.16x | 2.16x |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A | 802.02x | 903.36x | 873.57x |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | N/A | 1162726.42x | 640219.29x | 640219.29x |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | 24.52x | 19.77x | 15.30x | 133.58x |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | 0.76x | 0.33x | 0.31x | 0.34x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
